{"classes":[{"categories":[{"measurements":[{"groupId":"OG003","spread":"48633.55","value":"54688.25"}]}],"title":"Day 0"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"47953.53","value":"159239.75"}]}],"title":"Day 7"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"43692.86","value":"55328.25"}]}],"title":"Day 14"},{"categories":[{"measurements":[{"groupId":"OG003","spread":"135922.69","value":"127911.25"}]}],"title":"Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}],"units":"Participants"}],"description":"Mutation burden as detected by comparing the TCR sequencing of tumor tissue and/or PBMC. Mean numbers of clonotypes were reported by time point with standard deviations.","dispersionType":"Standard Deviation","groups":[{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.1 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG000","title":"Stratum 1, Dose Level 1"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG001","title":"Stratum 1, Dose Level 2"},{"description":"Patients with recurrent or refractory primary malignant CNS tumors received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG002","title":"Stratum 1, Dose Level 3"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.3 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG003","title":"Stratum 2, Dose Level 2"},{"description":"Patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) received APX005M on day 1 of each 21-day course at 0.6 mg/kg for up to 36 courses or until disease progression, unacceptable toxicity, or death.","id":"OG004","title":"Stratum 2, Dose Level 3"}],"paramType":"MEAN","populationDescription":"Only 4 Stratum 2 patients had data available for this analysis.","reportingStatus":"POSTED","timeFrame":"Day 0 and Days 7, 14, and 21 after the start of treatment","title":"Mutation Burden Based on TCR Sequencing","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Clonotyes"}